Information Provided By: 
Fly News Breaks for March 19, 2019
NVCR
Mar 19, 2019 | 16:45 EDT
SunTrust analyst Gregg Gilbert started Novocure with a Hold rating and $50 price target. The analyst believes the shares now reflect investor optimism for continued growth of Optune in glioblastoma, Medicare coverage for Optune, a mesothelioma approval, and the potential for Optune to have utility in larger indications. While Gilbert does not see enough near-term upside for a Buy rating, he believes Novocure has the potential for "significant" upside over the next few years.
News For NVCR From the Last 2 Days
There are no results for your query NVCR
